U.S. markets closed
  • S&P Futures

    3,286.50
    +23.00 (+0.70%)
     
  • Dow Futures

    26,603.00
    +194.00 (+0.73%)
     
  • Nasdaq Futures

    11,201.25
    +68.50 (+0.62%)
     
  • Russell 2000 Futures

    1,549.20
    +10.00 (+0.65%)
     
  • Crude Oil

    37.58
    +0.19 (+0.51%)
     
  • Gold

    1,880.30
    +1.10 (+0.06%)
     
  • Silver

    23.50
    +0.14 (+0.58%)
     
  • EUR/USD

    1.1756
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    0.7810
    +0.0030 (+0.39%)
     
  • Vix

    40.28
    +6.93 (+20.78%)
     
  • GBP/USD

    1.2994
    +0.0007 (+0.06%)
     
  • USD/JPY

    104.3060
    +0.0050 (+0.00%)
     
  • BTC-USD

    13,293.05
    +35.38 (+0.27%)
     
  • CMC Crypto 200

    262.71
    -9.98 (-3.66%)
     
  • FTSE 100

    5,582.80
    -146.19 (-2.55%)
     
  • Nikkei 225

    23,182.66
    -235.85 (-1.01%)
     

These 3 Falling Knives Are Expected to Outperform

GuruFocus.com

- By Alberto Abaterusso

After declining more than 59% over the past year through April 11, the following falling knives may be appealing to investors who believe they can outperform the overall market over the next 52 weeks as a result of strong recommendation ratings.

Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives.


Here are the results of my search:

Nektar Therapeutics Inc. (NKTR) closed at $35.75 per share on Thursday after a 60% decline over the past year through April 11, sending the price below the 200-, 100- and 50-day simple moving average lines. The closing price on Thursday was 22.5% off the 52-week low of $29.22 and 193% from the 52-week high of $104.88.

The San Francisco-based biotech company's market capitalization is $6.22 billion. The price-earnings ratio is 9.93 versus the industry median of 28.79, the price-book ratio is 3.60 versus the industry median of 4.10 and the price-sales ratio is 5.43.

GuruFocus assigned a financial strength rating of 8 out of 10 and a profitability and growth rating of 7 out of 10.

Wall Street issued an average target price of $70.83, reflecting 98% upside from the closing price on Thursday.

The 14-day relative strength index of 51.17 suggests the stock is neither overbought nor oversold.

Shares of Stamps.com Inc. (STMP) closed at $78.6 on Thursday for a market capitalization of approximately $1.4 billion. The stock declined 61% over the last 52 weeks through April 11, sending the share price below the 200-, 100- and 50-day simple moving average lines. The 52-week range is $77.57 to $285.75.

Headquartered in California, the provider of internet-based mailing and shipping solutions has a price-earnings ratio of 8.87 versus the industry median of 24.79, a price-book ratio of 2.40 versus the industry median of 2.93 and a price-sales ratio of 2.55 compared to the industry median of 2.86.

GuruFocus assigned a financial strength rating of 8 out of 10 and a profitability and growth rating of 9 out of 10.

Wall Street issued an average target price of $159.60, reflecting 103% upside from Thursday's closing price.

The 14-day relative strength index of 28.47 suggests the stock is approaching oversold levels.

Shares of Adaptimmune Therapeutics PLC (ADAP) closed at $4.4 on Thursday for a market capitalization of $458.64 million. The stock has declined 65% over the past year through April 11.

The chart below shows the stock is trading near the 50-day simple moving average line, but below the 200- and 100-day lines. The closing share price on Thursday was 24% above the 52-week low of $3.55 and 232.5% below the 52-week high of $14.63.

936598800.jpg
936598800.jpg

The U.K.-based biotech company has a price-book ratio of 1.85 versus the industry median of 4.1 and a price-sales ratio of 7.35.

GuruFocus assigned a financial strength rating of 10 out of 10 and a profitability and growth rating of 2 out of 10.

Wall Street issued an average target price of $13, which represents a 195.5% growth from the closing price on Thursday.

The 14-day relative strength index of 48.72 suggests the stock is neither oversold nor overbought.

Disclosure: I have no positions in any securities mentioned.

Read more here:



Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here .

This article first appeared on GuruFocus.